These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1706188)

  • 21. A recombinant HIV gag p17 protein suppresses the function of normal T cells.
    Eugen-Olsen J; Koppelhus U; Andresen L; Nielsen JO; Hofmann B
    Biochem Soc Trans; 1997 May; 25(2):220S. PubMed ID: 9191264
    [No Abstract]   [Full Text] [Related]  

  • 22. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.
    Weaver EA; Lu Z; Camacho ZT; Moukdar F; Liao HX; Ma BJ; Muldoon M; Theiler J; Nabel GJ; Letvin NL; Korber BT; Hahn BH; Haynes BF; Gao F
    J Virol; 2006 Jul; 80(14):6745-56. PubMed ID: 16809280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of HIV peptide epitopes by a novel algorithm.
    Roberts CG; Meister GE; Jesdale BM; Lieberman J; Berzofsky JA; De Groot AS
    AIDS Res Hum Retroviruses; 1996 May; 12(7):593-610. PubMed ID: 8743085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types.
    Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
    Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157
    [No Abstract]   [Full Text] [Related]  

  • 25. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine.
    Gahéry-Ségard H; Pialoux G; Charmeteau B; Sermet S; Poncelet H; Raux M; Tartar A; Lévy JP; Gras-Masse H; Guillet JG
    J Virol; 2000 Feb; 74(4):1694-703. PubMed ID: 10644339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46.
    Lairmore MD; Rudolph DL; Roberts BD; Dezzutti CS; Lal RB
    Cancer Lett; 1992 Sep; 66(1):11-20. PubMed ID: 1360328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epitope mapping of a monoclonal antibody which binds HIV-1 Gag and not the Gag-derived proteins.
    Sarubbi E; Denaro M
    FEBS Lett; 1993 Dec; 335(3):335-7. PubMed ID: 7505237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
    Schirmbeck R; Deml L; Melber K; Wolf H; Wagner R; Reimann J
    Vaccine; 1995 Jun; 13(9):857-65. PubMed ID: 7483809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preferential V beta usage by cytotoxic T cells cross-reactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction.
    Shirai M; Vacchio MS; Hodes RJ; Berzofsky JA
    J Immunol; 1993 Aug; 151(4):2283-95. PubMed ID: 7688397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
    Zaghouani H; Hall B; Shah H; Bona C
    Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
    [No Abstract]   [Full Text] [Related]  

  • 33. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes.
    Zaghouani H; Goldstein D; Shah H; Anderson S; Lacroix M; Dionne G; Kennedy R; Bona C
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5645-9. PubMed ID: 2062842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
    Shirai M; Pendleton CD; Berzofsky JA
    J Immunol; 1992 Mar; 148(6):1657-67. PubMed ID: 1371784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 transgenic mice.
    Schönbach C; Nokihara K; Bangham CR; Kariyone A; Karaki S; Shida H; Takatsu K; Egawa K; Wiesmüller KH; Takiguchi M
    Virology; 1996 Dec; 226(1):102-12. PubMed ID: 8941327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a potent synthetic HIV1 immunogen compromising gag-P24 tandem T- and B-cell epitopes.
    Chong P; Sia C; Sydor M; Klein M
    FEBS Lett; 1990 May; 264(2):231-4. PubMed ID: 1694143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of CD4+ T cell activation and adhesion by peptides derived from the gp160.
    Corado J; Mazerolles F; Le Deist F; Barbat C; Kaczorek M; Fischer A
    J Immunol; 1991 Jul; 147(2):475-82. PubMed ID: 1677023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
    Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
    AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.
    Bergmann C; Stohlmann SA; McMillan M
    Eur J Immunol; 1993 Nov; 23(11):2777-81. PubMed ID: 7693478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.